Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Key Highlights
- ➤Peter Greenleaf and Alex Howarth join Altimmune’s board effective November 2, 2026
- ➤Three directors will retire and not stand for reelection at the 2027 Annual Meeting
- ➤Phase 3 MASH trial funded and ongoing, with Phase 2 AUD data reported as outstanding
- ➤Pemvidutide advances across MASH, AUD and ALD indications in late-stage development
Expert Statements
Jerry Durso, CEO and Chairman of the Board of Altimmune
“We are thrilled to welcome Peter and Alex to the Altimmune Board of Directors”
Jerry Durso, CEO and Chairman of the Board of Altimmune
“These two proven executive industry leaders bring strategic perspectives in drug development, commercialization and corporate development that will be a valuable addition to the Altimmune Board as we continue to progress pemvidutide as a differentiated liver franchise.”
Jerry Durso, CEO and Chairman of the Board of Altimmune
“With our Phase 3 MASH trial funded and ongoing, along with outstanding Phase 2 data in AUD, now is the right time to evolve our Board of Directors.”
Jerry Durso, CEO and Chairman of the Board of Altimmune
“On behalf of the Board of Directors, I would like to thank John, Mitch and Klaus for their long-term contributions to Altimmune, culminating with the significant progress that we believe will enable a successful future addressing serious liver diseases,”
Jerry Durso, CEO and Chairman of the Board of Altimmune
“Important milestones achieved for the Company include accelerating the clinical development of pemvidutide, rebuilding the management team with late-stage development capabilities, and securing needed financing.”
Jerry Durso, CEO and Chairman of the Board of Altimmune
“This Board succession plan is intended to build on our momentum.”
Peter Greenleaf, Board member of Altimmune
“Altimmune’s exceptional recent progress has positioned it for a successful transition into a late-stage development company,”
Peter Greenleaf, Board member of Altimmune
“I look forward to working with the Board and management team in our efforts to establish Altimmune as a potential category leader in the treatment of liver diseases and fully realize the strategic value of pemvidutide.”
Alex Howarth, Board member of Altimmune
“Altimmune’s strategic plan and balance sheet are strong, offering significant leverage to support future growth,”
Alex Howarth, Board member of Altimmune
“I am eager to work with my Board colleagues to capitalize on these and other drivers to move pemvidutide quickly and efficiently through Phase 3 development and towards commercialization.”
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications
As part of this transition, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board at the Company’s 2027 Annual Meeting
Get started
Create a free account to read the full story.